REFERENCES
- Allo MD, Bennion RS, Kathir K, et al. Ticarcillin/clavu-lanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 1999; 65: 99–104.
- Heseltine PNR, Yellin AE, Appleman MD, et al. Imipenem therapy for perforated and gangrenous appendicitis. Surg Gynecol Obstet 1986; 162: 43–8.
- Heseltine PNR, Yellin AE, Appleman MD, Gill MA, Chenella FC, Berne TV. Perforated and gangrenous appendicitis: an analysis of antibiotic failures. J Infect Dis 148; 322: 1983.
- Bennion RS, Thompson JE, Baron EJ, Finegold SM. Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. Clin Therapeut 1990; 12 (Suppl. C): 31–44.
- Berne TV, Yellin AE, Appleman MD, Heseltine PNR., Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appen-dicitis. J Am Coll Surg 1996; 182: 403–7.
- Bohnen JMA, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for critical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992; 127: 83–9.
- Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect 2002; 3: 161–73.
- Buie PS. Management of complicated intra-abdominal infections. J Chemother 1999; 11: 464–77.
- Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from North American medical centers. Antimicrob Agents Chemother 2001; 45: 1915–8.
- Aldridge K. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaer-obes. Diagn Microbiol Infect Dis 2002; 44: 181–6.
- Friedland I, Mixson LA, Majumdar A, Motyl M, Woods GL. In vitro activity of ertapenem against common clinical iso-lates in relation to human pharmacokinetics. J Chemother 2002; 14: 483–91.
- Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: Results of a double-blind, random-ized comparative phase III trial. Ann Surg 2003; 237: 235–45.
- Beam TR. Jr, Gilbert DN, Kunin DM. General guide-lines for the clinical evaluation of anti-infective drug products. Clin Infect Dis 1992; 15 (Suppl 1): S5–32.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacte-ria that grow aerobically, 5th ed. NCCLS document M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
- National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved Standard, M11-A5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2001.
- Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother ( in press).
- Gesser R, Teppler H, McCarroll K, Woods G. Efficacy of ertapenem in treatment of Escherichia coli infections [abstr P774]. Clin Microbiol Infect 2002; 8 (Suppl. 1): 160.
- Teppler H, McCarroll K, Gesser RM, Woods GL. Surgical infections with Enterococcus: Outcome in patients treated with ertapenem versus piperacillin-tazobactam. Surg Infect 2002; 3: 337–49.
- Buie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronida-zole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg 1997; 132: 1294–1302.
- Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of enterococcus in intraabdominal infec-tion: Analysis of a prospective randomized trial. Surgery 1995; 118: 716–23.
- Wilson SE, Faulkner K, Biol C, Biol MI. Impact of anatomical site on bacteriological and clinical outcome in the management of intra-abdominal infections. Am Surg 1998; 64: 402–7.